Anti CD-6 Monoclonal Antibodies in the Management of Generalised Pustular Psoriasis
Copyright: © 2022 Indian Journal of Dermatology..
Generalised pustular psoriasis (GPP) is an uncommon, severe, life-threatening variant of psoriasis requiring careful therapeutic approach. Conventional treatment modalities have unsatisfactory outcomes, poor side effect profiles and toxicities that have led to an emerging use of biological therapies. Itolizumab, an anti-CD-6 humanised monoclonal IgG1 antibody, is approved for the management of chronic plaque psoriasis in India. We share our experience of using this drug in three cases of GPP that were failing conventional therapies. Its upstream effect on co-stimulatory pathway in disease pathogenesis is the postulated mechanism. Our experience warrants further large-scale exploration of the role of itolizumab in the management of GPP, which would benefit this severely affected population of patients. Although the definite pathogenesis of GPP is unknown fully, molecules blocking CD-6, which plays a role in the interaction between T cells and antigen-presenting cells (APCs), are expected as new promising treatment options for GPP.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:67 |
|---|---|
| Enthalten in: |
Indian journal of dermatology - 67(2022), 5 vom: 15. Sept., Seite 568-572 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kura, Mahendra M [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anti-CD-6 |
|---|
| Anmerkungen: |
Date Revised 31.10.2023 published: Print Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.4103/ijd.ijd_180_21 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM353717894 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM353717894 | ||
| 003 | DE-627 | ||
| 005 | 20231226060645.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4103/ijd.ijd_180_21 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1179.xml |
| 035 | |a (DE-627)NLM353717894 | ||
| 035 | |a (NLM)36865872 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kura, Mahendra M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Anti CD-6 Monoclonal Antibodies in the Management of Generalised Pustular Psoriasis |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 31.10.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Copyright: © 2022 Indian Journal of Dermatology. | ||
| 520 | |a Generalised pustular psoriasis (GPP) is an uncommon, severe, life-threatening variant of psoriasis requiring careful therapeutic approach. Conventional treatment modalities have unsatisfactory outcomes, poor side effect profiles and toxicities that have led to an emerging use of biological therapies. Itolizumab, an anti-CD-6 humanised monoclonal IgG1 antibody, is approved for the management of chronic plaque psoriasis in India. We share our experience of using this drug in three cases of GPP that were failing conventional therapies. Its upstream effect on co-stimulatory pathway in disease pathogenesis is the postulated mechanism. Our experience warrants further large-scale exploration of the role of itolizumab in the management of GPP, which would benefit this severely affected population of patients. Although the definite pathogenesis of GPP is unknown fully, molecules blocking CD-6, which plays a role in the interaction between T cells and antigen-presenting cells (APCs), are expected as new promising treatment options for GPP | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Anti-CD-6 | |
| 650 | 4 | |a biological agents | |
| 650 | 4 | |a generalised pustular psoriasis | |
| 650 | 4 | |a humanised IgG1 monoclonal antibody | |
| 650 | 4 | |a itolizumab | |
| 700 | 1 | |a Sodhi, Anmol |e verfasserin |4 aut | |
| 700 | 1 | |a Sajgane, Avinash |e verfasserin |4 aut | |
| 700 | 1 | |a Karande, Ashish |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Indian journal of dermatology |d 1962 |g 67(2022), 5 vom: 15. Sept., Seite 568-572 |w (DE-627)NLM000655279 |x 1998-3611 |7 nnns |
| 773 | 1 | 8 | |g volume:67 |g year:2022 |g number:5 |g day:15 |g month:09 |g pages:568-572 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.4103/ijd.ijd_180_21 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 67 |j 2022 |e 5 |b 15 |c 09 |h 568-572 | ||